Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib + venetoclax with or without obinutuzumab versus chemoimmunotherapy in previously untreated chronic lymphocytic leukemia
NL-OMON52519Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- May 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of acalabrutinib, venetoclax and obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (3 arms), sponsored by AstraZeneca. Primary endpoint: Progression-free survival. Started May 2020; status: recruiting.
02
Drugs
acalabrutinibvenetoclaxobinutuzumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on NL-OMON52519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52519.